High Court's Myriad Ruling Won't Crush Biotech Industry

Law360, New York (June 13, 2013, 10:10 PM EDT) -- The U.S. Supreme Court’s ruling Thursday invalidating Myriad Genetics Inc.’s patents on isolated human genes won’t deal a serious financial blow to the biotechnology industry, and could even strengthen it by allowing intellectual property protections for synthetic DNA and giving scientists greater leeway to experiment with genetic material, experts say.

The likely impact on Myriad's $3,000 cancer-risk test shows how the ruling cuts both ways. Researchers are now free to experiment with the genes Myriad isolated, known as BRCA1 and BRCA2, but they’ll have to avoid infringing...
To view the full article, register now.